Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Shares Outstanding (Weighted Average) (2016 - 2025)

Cytokinetics (CYTK) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $120103.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) changed N/A to $120103.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $120103.0, a N/A change, with the full-year FY2025 number at $120103.0, changed N/A from a year prior.
  • Shares Outstanding (Weighted Average) was $120103.0 for Q4 2025 at Cytokinetics, up from $119317.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $120103.0 in Q4 2025 to a low of $71195.0 in Q1 2021.
  • A 5-year average of $96217.7 and a median of $95461.0 in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 22.5% in 2024, then increased 1.39% in 2025.
  • Cytokinetics' Shares Outstanding (Weighted Average) stood at $76886.0 in 2021, then grew by 16.83% to $89825.0 in 2022, then grew by 7.46% to $96524.0 in 2023, then grew by 21.92% to $117685.0 in 2024, then rose by 2.05% to $120103.0 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Shares Outstanding (Weighted Average) are $120103.0 (Q4 2025), $119317.0 (Q3 2025), and $118979.0 (Q2 2025).